Drugmaker Pfizer’s 1Q profit drops 15 pct as generic competition, other factors cut sales

NEW YORK, N.Y. – The drugmaker Pfizer says its first-quarter profit dropped 15 per cent due to cheaper generic competition that continues to reduce sales of its multiple medicines and the end of some partnerships with other drug makers.

The maker of Viagra says net income was $2.33 billion, or 36 cents per share, for the January-March period. That’s down from $2.75 billion, or 38 cents per share, a year earlier.

Excluding one-time charges, income was 57 cents per share. Analysts surveyed by FactSet expected 55 cents per share.

Revenue totalled $11.35 billion, down 9 per cent. Analysts expected $12.08 billion.

Pfizer, which recently has made three unsuccessful offers to acquire rival AstraZeneca Plc, confirmed its 2014 profit forecast for earnings per share of $2.20 to $2.30 and revenue of $49.2 billion to $52.3 billion.

News from © The Associated Press, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.

The Associated Press

The Associated Press is an independent global news organization dedicated to factual reporting. Founded in 1846, AP today remains the most trusted source of fast, accurate, unbiased news in all formats and the essential provider of the technology and services vital to the news business. More than half the world’s population sees AP journalism every day.